Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
Introduced
In Committee
On Floor
Passed Chamber
Enacted
Pass-Through Technical Corrections Act This bill specifically extends the duration of pass-through status (i.e., additional payment) for certain radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. In particular, the bill provides that a radiopharmaceutical with an indication for certain PET imaging that is covered in relation to clinical studies (i.e., coverage with evidence development) continues to receive pass-through status until the applicable coverage review is complete, if such status initially expired on either December 31, 2017, or December 31, 2018.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Health
Drug therapyHome and outpatient careHospital careMedicare
Pass-Through Technical Corrections Act
USA116th CongressHR-5057| House
| Updated: 11/13/2019
Pass-Through Technical Corrections Act This bill specifically extends the duration of pass-through status (i.e., additional payment) for certain radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. In particular, the bill provides that a radiopharmaceutical with an indication for certain PET imaging that is covered in relation to clinical studies (i.e., coverage with evidence development) continues to receive pass-through status until the applicable coverage review is complete, if such status initially expired on either December 31, 2017, or December 31, 2018.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.